Furthermore, the decrease of tumor cells in the group treated with Srb1 correlated with a 2.66-fold survival increase (p=0.00000692), as compared with the isotype control treated animals (from 156.6 ± 37.6 days to 58.7 ± 2.9 days, respectively) (Figures 5G, H). Here, SCARB1 is linked to neoplasm.